NYSE:GSK GSK (GSK) Stock Price, News & Analysis $47.25 +0.65 (+1.40%) As of 11:32 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About GSK Stock (NYSE:GSK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GSK alerts:Sign Up Key Stats Today's Range$46.69▼$47.2050-Day Range$46.54▼$53.1552-Week Range$42.85▼$61.69Volume1.89 million shsAverage Volume4.37 million shsMarket Capitalization$95.58 billionP/E Ratio14.79Dividend Yield3.77%Price Target$56.50Consensus RatingHold Company Overview GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies. GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions. Through ViiV Healthcare, in which GSK is the majority shareholder, the company also provides HIV treatments, including therapies based on dolutegravir. The company traces its modern history to the 2000 merger of Glaxo Wellcome and SmithKline Beecham. In 2022, GSK separated its consumer healthcare business, which became Haleon, allowing GSK to focus exclusively on biopharmaceuticals. GSK is led by Chief Executive Officer Emma Walmsley, who has held the role since 2017.AI Generated. May Contain Errors. Read More GSK Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreGSK MarketRank™: GSK scored higher than 80% of companies evaluated by MarketBeat, and ranked 121st out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingGSK has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 1 strong buy rating, 1 buy rating, 7 hold ratings, and 2 sell ratings.Upside PotentialGSK has a consensus price target of $56.50, representing about 21.1% upside from its current price of $46.64.Amount of Analyst CoverageGSK has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GSK's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.80% Earnings GrowthEarnings for GSK are expected to grow by 4.80% in the coming year, from $4.79 to $5.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 14.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.02.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 14.58, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.94.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.96. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GSK's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.80% of the float of GSK has been sold short.Short Interest Ratio / Days to CoverGSK has a short interest ratio ("days to cover") of 5.51.Change versus previous monthShort interest in GSK has recently increased by 8.16%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 3.82%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 55.63%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, GSK will have a dividend payout ratio of 35.46% next year. This indicates that GSK will be able to sustain or increase its dividend.Read more about GSK's dividend. News and Social Media2.1 / 5News Sentiment0.37 News SentimentGSK has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for GSK this week, compared to 6 articles on an average week.Search InterestOnly 25 people have searched for GSK on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows14 people have added GSK to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GSK insiders have not sold or bought any company stock.Percentage Held by Insiders10.00% of the stock of GSK is held by insiders.Percentage Held by Institutions15.74% of the stock of GSK is held by institutions.Read more about GSK's insider trading history. Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GSK Stock News HeadlinesGSK: The Gas Pedal Is Finally Down32 minutes ago | seekingalpha.comGSK's ViiV Healthcare Says HIV Treatment Cabenuva's Latest Trial Meets Primary EndpointOctober 6 at 12:18 PM | finance.yahoo.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 7 at 1:00 AM | Stansberry Research (Ad)ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremiaOctober 6 at 12:18 PM | finance.yahoo.comHead to Head Analysis: CorMedix (NASDAQ:CRMD) versus GSK (NYSE:GSK)October 6 at 4:58 AM | americanbankingnews.comAbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilotOctober 3, 2026 | msn.comGSK India sets Guinness World Record with massive healthcare mosaic in MumbaiSeptember 29, 2026 | msn.comGSK India sets Guinness World Records title with giant brochure mosaic on World Heart DaySeptember 29, 2026 | msn.comSee More Headlines GSK Stock Analysis - Frequently Asked Questions How have GSK shares performed this year? GSK's stock was trading at $49.06 at the beginning of the year. Since then, GSK shares have decreased by 4.9% and is now trading at $46.6370. How were GSK's earnings last quarter? GSK PLC Sponsored ADR (NYSE:GSK) issued its earnings results on Tuesday, July, 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.09. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. Read the conference call transcript. Who are GSK's major shareholders? GSK's top institutional shareholders include Parrish Capital LLC, Versant Capital Management Inc, Central Pacific Bank Trust Division and Rockland Trust Co.. View institutional ownership trends. How do I buy shares of GSK? Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some other companies that GSK investors own include Chevron (CVX), BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), Bristol Myers Squibb (BMY), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Record date for 7/9 Dividend5/15/2026Ex-Dividend for 7/9 Dividend5/15/2026Dividend Payable7/09/2026Last Earnings7/28/2026Record date for 10/8 Dividend8/14/2026Ex-Dividend for 10/8 Dividend8/14/2026Today10/07/2026Dividend Payable10/08/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GSK's financial health is in the Red zone, according to TradeSmith. GSK has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:GSK CIK1131399 Webwww.gsk.com Phone442080475000Fax44-20-8047-7807Employees66,841Year Founded2000Price Target and Rating Average Price Target for GSK$56.50 High Price Target$60.00 Low Price Target$53.00 Potential Upside/Downside+19.6%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$3.20 Trailing P/E Ratio14.79 Forward P/E Ratio9.87 P/E Growth1.96Net Income$7.54 billion Net Margins14.56% Pretax Margin17.84% Return on Equity43.23% Return on Assets11.60% Debt Debt-to-Equity Ratio0.81 Current Ratio0.82 Quick Ratio0.52 Sales & Book Value Annual Sales$43.07 billion Price / Sales2.22 Cash Flow$6.10 per share Price / Cash Flow7.75 Book Value$10.32 per share Price / Book4.58Miscellaneous Outstanding Shares2,022,710,000Free Float1,820,435,000Market Cap$95.58 billion OptionableOptionable Beta0.33 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:GSK) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
